Cheng H, Polvino W J, Sciberras D, Yogendran L, Cerchio K A, Christie K, Olah T V, McLoughlin D, James I, Rogers J D
Merck Research Laboratories, West Point, PA 19486, USA.
Biopharm Drug Dispos. 1996 Jan;17(1):17-24. doi: 10.1002/(SICI)1099-081X(199601)17:1<17::AID-BDD932>3.0.CO;2-F.
A study was conducted to assess the safety, tolerability, and pharmacokinetics of single intravenous (IV) doses of 5-90 micrograms kg-1 of MK-462, and the effect of food on the pharmacokinetics of MK-462 administered orally to healthy males. Results of this study indicate that IV doses of MK-462 from 5 to 90 micrograms kg-1 are well tolerated. The disposition kinetics of MK-462 were linear for IV doses up to and including 60 micrograms kg-1. The values of the plasma clearance (CL), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRT) of MK-462 averaged 1376 mL min-1, 140 L, 1.8 h, and 1.7 h, respectively, and remained essentially constant over the dosage range of 10-60 micrograms kg-1 of IV MK-462. However, as the dose increased from 60 to 90 micrograms kg-1, the mean value of the apparent CL decreased from 1376 to 807 mL min-1. Thus, elimination of MK-462 was dose dependent in this dosage range. Based on the disposition decomposition analysis (DDA), it was shown that the Vss value of MK-462 remained essentially constant over the dosage range of 10-90 micrograms kg-1 of IV MK-462. The following values of two dose-independent parameters were also calculated by using DDA: distribution clearance (CLd) = 2028 mL min-1, and mean transit time in the peripheral tissues (MTTT) = 0.74 h. The mean values of AUC, Cmax, tmax, and apparent t1/2 of MK-462 in 12 subjects each receiving a 40 mg tablet of MK-462 without breakfast were 330 ng.h mL-1, 77 ng mL-1, 1.6 h, and 1.8 h, respectively. Although administration of a standard breakfast prior to dosing increased the AUC value (by approximately 20%) of MK-462 and delayed its absorption, there were no significant effects of the meal on the values of Cmax and apparent t1/2 of MK-462.
开展了一项研究,以评估单次静脉注射5 - 90微克/千克的MK - 462的安全性、耐受性和药代动力学,以及食物对健康男性口服MK - 462药代动力学的影响。该研究结果表明,静脉注射5至90微克/千克的MK - 462耐受性良好。对于高达并包括60微克/千克的静脉注射剂量,MK - 462的处置动力学呈线性。MK - 462的血浆清除率(CL)、稳态分布容积(Vss)、血浆末端半衰期(t1/2)以及在体内的平均驻留时间(MRT)的值分别平均为1376毫升/分钟、140升、1.8小时和1.7小时,并且在10 - 60微克/千克的静脉注射MK - 462剂量范围内基本保持恒定。然而,当剂量从60微克/千克增加到90微克/千克时,表观CL的平均值从1376降至807毫升/分钟。因此,在该剂量范围内,MK - 462的消除呈剂量依赖性。基于处置分解分析(DDA),结果显示在10 - 90微克/千克的静脉注射MK - 462剂量范围内,MK - 462的Vss值基本保持恒定。还通过使用DDA计算了两个非剂量依赖性参数的以下值:分布清除率(CLd)= 2028毫升/分钟,外周组织平均通过时间(MTTT)= 0.74小时。12名受试者每人服用一片40毫克的MK - 462且未吃早餐,MK - 462的AUC、Cmax、tmax和表观t1/2的平均值分别为330纳克·小时/毫升、77纳克/毫升、1.6小时和1.8小时。尽管在给药前食用标准早餐会增加MK - 462的AUC值(约20%)并延迟其吸收,但该餐食对MK - 462的Cmax和表观t1/2值没有显著影响。